AmySehnertMD

Pediatric Cardiology • San Francisco, CA

Vice President, Clinical Science

Join to view full profile

Dr. Sehnert is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sehnert's full profile

Already have an account?

Office
331 Panorama Drive
San Francisco, CA 94131
Phone+1 415-297-6428

Education & Training

University of California (San Francisco)Fellowship, Pediatric Cardiology, 1995 - 1999
University of ColoradoResidency, Pediatrics, 1992 - 1995
University of Minnesota Medical SchoolClass of 1992

Certifications & Licensure

CA State Medical License 1995 - 2025

Clinical Trials

Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial Start of enrollment: 2007 Jan 01
Completed
MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy Start of enrollment: 2010 Jun 01
Completed
Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Start of enrollment: 2018 May 29
Completed
Phase 3
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER Start of enrollment: 2018 Apr 26
Completed
Phase 2
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Start of enrollment: 2018 Oct 05
Active, not recruiting
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Sharon Cresci, Richard G Bach, Sara Saberi, Anjali T Owens, John A Spertus
Circulation. 2024-02-13
4 citations
Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.
Konstantinos C Siontis, Sean Abreau, Zachi I Attia, Joshua P Barrios, Thomas A Dewland
JACC. Advances. 2023-10-01
36 citations
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Milind Y Desai, Anjali Owens, Jeffrey B Geske, Kathy Wolski, Sara Saberi
Circulation. 2023-03-14

Press Mentions

Using AI in Electrocardiogram Analysis Can Improve Diagnosis and Treatment of Hypertrophic CardiomyopathyMarch 7th, 2022
Results from Two Phase 3 Studies Evaluating CAMZYOS (Mavacamten) for Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM) Released by Bristol Myers SquibbSeptember 6th, 2023
Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy ReleasedSeptember 10th, 2023